VistaGen Therapeutics Newsroom

Earnings Preview: VTGN to Report Financial Results Post-market on November 07

$VistaGen Therapeutics(VTGN.US)$ is scheduled to release its financial results post-market on November 07 ET. Earnings PreviewAnalysts estimate $VistaGen Therapeutics(VTGN.US)$ to post revenue of USD3

Futu NewsNov 1 22:45

Press Release: Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024

Dow JonesNov 1 20:31

Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day

BusinesswireOct 9 20:30

All You Need to Know About VistaGen Therapeutics (VTGN) Rating Upgrade to Buy

Yahoo FinanceSep 7 00:00

Companies Like Vistagen Therapeutics (NASDAQ:VTGN) Are In A Position To Invest In Growth

Yahoo FinanceSep 5 22:14

Maxim Group Maintains VistaGen Therapeutics(VTGN.US) With Buy Rating, Maintains Target Price $12

Maxim Group analyst Jason McCarthy maintains $VistaGen Therapeutics(VTGN.US)$ with a buy rating, and maintains the target price at $12.According to TipRanks data, the analyst has a success rate of 23.

Futu NewsAug 15 20:31 · Ratings

Buy Rating Affirmed on VistaGen Therapeutics Amid Strong Financials and Promising Clinical Trials

TipRanksAug 15 19:46 · Ratings

Earnings Call Summary | VistaGen Therapeutics(VTGN.US) Q1 2025 Earnings Conference

Futu NewsAug 14 11:46 · Conference Call

VistaGen Therapeutics | 10-Q: Q1 2025 Earnings Report

SECAug 14 04:52 · Announcements

VistaGen Therapeutics Q1 2025 Adj EPS $(0.35) Beats $(0.41) Estimate, Sales $84.00K Miss $300.00K Estimate

BenzingaAug 14 04:23

Express News | Vistagen Therapeutics Inc - Palisade Phase 3 Program for Acute Treatment of Social Anxiety Disorder Progressing on Track

BreakingsAug 14 04:21

Vistagen Therapeutics 1Q Loss/Shr 35c >VTGN

Dow JonesAug 14 04:21

Express News | Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update

BreakingsAug 14 04:21

Here's the Major Earnings After the Close Today

Seeking AlphaAug 13 22:00

VistaGen Therapeutics Q1 2025 Earnings Preview

Seeking AlphaAug 13 05:35

Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024

BusinesswireAug 6 20:30

Vistagen Expands Global Intellectual Property Portfolio With New Patents For PH80 Nasal Spray; Investigational Treatment For Migraine, Hot Flashes Due To Menopause, Premenstrual Dysphoric Disorder, And Dysmenorrhea

BenzingaJul 9 20:34

Express News | Vistagen Therapeutics Inc: All of New Patents Are Expected to Be in Effect Until 2040

BreakingsJul 9 20:30

Express News | Vistagen Broadens Ph80 Global Intellectual Property Portfolio With New Patents for the Treatment of Migraine

BreakingsJul 9 20:30

Vistagen Awarded Mental Health America's Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year

BusinesswireJun 27 20:30